Loading clinical trials...
Loading clinical trials...
An Observational Multi-Center Study Exploring the Association of Safety, Patient Characteristics, Virological, and Histological Parameters With Patient Outcome (Relapse Rate, Achievement of Sustained Viral Response in Daily Clinical Practice in Belgium- PEGIMPACT
Conditions
Interventions
PegIntron (peginterferon alfa-2b; SCH 54031)
Rebetol (ribavirin; SCH 18908)
Start Date
January 1, 2009
Primary Completion Date
March 1, 2010
Completion Date
March 1, 2010
Last Updated
August 11, 2014
NCT06953479
NCT03135886
NCT05968573
NCT05042544
NCT05870969
NCT05361603
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions